Nureca Peer Comparison

NSE: NURECA | BSE: 543264

₹304.30

₹2.00 (0.66%)

As on 08-Nov-2026IST

Market cap

₹287 Cr

Revenue (TTM)

₹174 Cr

P/E Ratio

60.3

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Market cap (₹ Cr)	287	16,192	193	102	51,585
Revenue (₹ Cr)	174	2,134	35	49	7,072
Net Profit (₹ Cr)	4.76	309.79	-6.02	9.45	1,235.87
Net Margin (%)	2.64	13.89	-16.77	18.21	16.75
RoE (%)	2.58	9.92	-37.67	22.13	11.91
Price to Earnings	60.31	50.86	--	10.78	41.74
Price-To-Book	1.53	4.96	17.74	1.96	4.83

Income Statement (₹ Cr)

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Operating Revenue	173.92	2,134.07	34.70	47.94	7,072.01
Total Income	180.30	2,230.51	35.90	51.08	7,376.93
Total Expenditure	167.80	1,649.83	35.88	37.82	5,150.71
EBITDA	6.12	484.24	-1.19	10.12	1,921.31
Depreciation	2.36	138.29	4.01	0.49	442.58
EBIT	3.76	345.95	-5.19	9.62	1,478.73
Interest	1.04	26.02	2.14	0.38	25.46
Other Income	6.38	96.44	1.21	3.14	304.92
Exceptional Items	0.00	2.76	-0.02	-0.41	-24.35
Profit before Tax	9.10	419.13	-6.14	11.97	1,733.84
Provision for Tax	4.34	109.35	-0.12	2.80	497.98
Profit after Tax	4.76	309.79	-6.02	9.17	1,235.87

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Shareholder's Funds	187.88	3,265.35	10.65	46.26	10,685.67
Minority Interest	0.00	2.13	1.83	0.00	0.00
Non-Current Liabilities	4.77	198.36	14.33	2.31	527.10
Current Liabilities	38.63	649.28	18.82	14.64	1,713.97
Total Liabilities	196.16	3,951.60	36.00	--	12,448.52

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Non-Current Assets	19.68	2,006.37	13.99	17.37	4,881.90
Current Assets	188.67	2,033.02	21.86	45.52	7,872.33
Total Assets	196.16	3,951.60	36.00	--	12,448.52
Total Debt*	0.72	341.62	9.65	--	243.36
Net Current Assets	150.04	1,383.74	3.04	30.88	6,158.36
Contingent Liabilities	4.73	50.21	--	--	10.12

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Cash From Operating Activities	3.30	246.37	-6.16	--	1,031.39
Cash Flow from Investing Activities	14.49	-225.38	-4.88	--	137.73
Cash from Financing Activities	-19.56	20.15	11.87	--	-416.97
Net Cash Inflow / Outflow	-1.77	41.14	0.84	--	752.14

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
ROCE (%)	3.31	14.05	-14.52	--	14.96
ROE (%)	2.58	9.92	-37.67	21.60	11.91
ROA (%)	2.09	8.00	-14.79	15.06	10.00
EBIT Margin (%)	2.16	16.21	-14.97	20.07	20.91
Net Margin (%)	2.64	13.89	-16.77	17.95	16.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Revenue Growth (%)	33.66	24.64	2.04	64.25	21.90
EBIT Growth (%)	268.37	-4.98	-282.68	245.16	49.42
Net Profit Growth (%)	15.95	-12.90	-257.42	144.10	56.36
EPS Growth (%)	21.52	-12.71	-205.68	118.12	58.48
Book Value Growth (%)	-6.96	12.14	535.42	--	12.70

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Price / Earnings	60.30	51.23	-42.73	6.22	41.12
Price / Book Value	1.53	4.96	17.74	1.97	4.83
Dividend Yield (%)	0.00	0.22	0.00	0.00	0.64
EV/EBITDA	40.10	32.44	-169.54	6.82	25.23
Market Cap (₹ Cr)	196.67	12,069.92	132.73	--	27,964.97

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Debt to Equity	0.01	0.01	0.50	0.00	0.01
Short term debt to equity ratio	0.00	0.08	0.35	--	--
Current Ratio	4.88	3.13	1.16	3.11	4.59
Quick Ratio	3.25	2.34	0.75	2.70	3.53
Interest Coverage	9.79	17.11	-1.87	32.33	69.10

	Nureca	Poly Medicure	Alan Scott	Maestros Electro	Gland Pharma
Debtors to sales (%)	15.59	26.19	3.58	16.67	27.25
Asset Turnover	0.76	0.55	0.85	0.79	0.57
Receivable days	12.70	85.20	6.53	--	96.72
Inventory Days	100.27	69.58	57.29	--	97.32
Payable days	22.92	77.97	18.72	--	134.60
Cash Conversion Cycle	90.04	76.82	45.09	--	59.43

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.